India’s ad market grew by just 9% in 2024, marking its slowest expansion since 2017 (excluding the pandemic-induced slump of ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

This experience tells us that weight loss is not all about the simple equation of calories in vs. calories out. Obesity isn’t ...

Introduction Globally, tuberculosis (TB) remains one of the leading infectious causes of death, with 1.3 million deaths.